Antitumor activities of 15-deoxyspergualin (NKT-01), an analogue of spergualin (SGL), were examinedin cultured tumor cells, transplantable murine tumors, and humantumor xenografts in nude mice. NKT-01exhibited strong antitumor activity specifically against leukemias both in vitro and in vivo. Moreover, it also showed activity against AH66Fhepatoma, M5076fibrosarcoma and MH134hepatoma. However, antitumor activity of NKT-01against other non-leukemic tumors was marginal. Effective dose range of NKT-01in sensitive tumors was so wide that the largest chemotherapeutic indexes were produced by NKT-01 in P388 and L1210 leukemias among 15 antitumor agents examined.
antitumor agents examined.
The efficacy of NKT-0 1 against doxorubicin-and cytosine arabinoside-resistant P388 leukemias wascomparable to that against parental sensitive P388 leukemia. NKT-01 also retained activity against other P388 leukemia sublines resistant to cisplatin, 5-fluorouracil or nimustine, although the effect was slightly decreased. In addition, in the in vitro and in vivo experiments using NKT-01-resistant P388 and SGL-resistant L1210(IMC) leukemias, no cross-resistance was observed. Moreover, collateral sensitivity was observed especially to alkylating agents in animal study.
Spergualin (SGL) is an antitumor antibiotic produced by a strain of Bacillus laterosporus.^It has strong antitumor activity against transplantable tumors as reported previously.2) Following determination of the structure of SGL,3) synthesis of SGL4)and its derivatives were performed.5~8) Through these studies structure-activity relationships were revealed and 15-deoxyspergualin (NKT-01) was selected for its strongest antitumor activity against L1210 leukemia in vivo. In addition to the antitumor activity, NKT-01 was also shown to have an immunosuppressive activity in both in vitro and in vivo systems.9'10) The clinical studies of NKT-01 as an antitumor drug and an immunosuppressant have been conducting.
In this paper, we report the details of the antitumor activity of NKT-01against various murine and humantumor cells in vitro and in vivo. Moreover, to knowthe uniqueness of the action of the drug, we assess whether NKT-01shows cross-resistance to other antitumor agents by using 5 strains ofP388 leukemia cells resistant to other antitumor agents and 2 resistatnt tumor cells to SGLs.
Materials and Methods

Drugs
SGL and NKT-01 were prepared by Takara Shuzo Co., Ltd. (Ohtsu, Japan), and dissolved in physiological saline and stored in dark at 4°C before use. Other antitumor drugs were purchased from commercial sources. OCT. 1991 Animals DBA/2, C57BL/6 (Charles River Japan Corp., Atsugi, Japan), CDFl5 BDF1? ICR (Shizuoka Laboratory Animal Center, Hamamatsu, Japan), C3H/He and BALB/c-nu/nu mice (Clea Japan Inc., Tokyo, Japan) and Donryurats (Nippon Rat Co., Urawa, Japan) were used in experiments at an age of 6 to 7 weeks. Each treatment group was composed of at least 6 animals. Tumors Weused 13 murine and 1 1 human tumor cell lines to examine the antitumor spectrum of NKT-01 in vitro and in vivo. Two strains of L1210 were used; one (L1210) was supplied by the Cancer Chemotherapy Center (Tokyo, Japan), which has been maintained in DBA/2 mice, and the other is its substrain, L1210 (IMC), maintained in CDFX mice at Institute of Microbial Chemistry (Tokyo, Japan).
P388 Leukemia resistant to NKT-01 (P388/NKT-01) and L1210(IMC) leukemia resistant to SGL (L1210(IMC)/SGL) were developed by the repetition of transplantations and daily treatment with 25.6mg/kg/day of NKT-01 and 50mg/kg/day of SGL in vivo, respectively.
Other resistant P388 leukemia cells (to nimustine (ACNU), cisplatin (CDDP), doxorubicin (ADM), 5-fluorouracil (5-FU), and cytosine arabinoside (Ara-Q) were also established by serial in vivo treatment with subtoxic dose of each drug.
Antitumor Experiments In Vitro
To compare the growth inhibitory activity of SGLand NKT-01, we used 14 kinds of tumors shown in Table 1 , among which 3 mouse leukemia cells and 2 rat hepatoma cells were primary cultured and grownin suspension. The other tumor cell lines were maintained in vitro as monolayerculture.
All cells were cultured in either RPMI-1640 (Gibco Labs., Chagrin Falls, U.S.) or MEMmedium (Flow Labs., McLean, U.S.) supplemented with 10% of human serum (Flow Labs.) and 60/xg/ml of kanamycin. Three mouse leukemia cell lines require addition of 5 jUMof 2-mercaptoethanol, and MOLT-3, NALM-6and Daudi cells were cultured in the presence of 1% of nonessential amino acid solution (Flow Labs.).
Growth rate was calculated from the cell number counted by Coulter Counter model ZBI before and after the exposure to drugs for a predetermined period. The growth inhibitory effect was assessed by comparing the growth rate of drug-treated cells and that of control, and then IC50 values were determined. THE JOURNAL OF ANTIBIOTICS OCT. 1991 Antitumor Experiments using Transplantable Murine Tumors
In order to obtain antitumor spectrum of NKT-01against transplantable tumors in vivo, weemployed 13 tumors maintained by serial transplantation in ascitic or solid form in our laboratories. Experimental host animals, inoculation sites and cell numbers used were summarized in Table 2 . NKT-01 was injected ip daily for 9 days from the day after the inoculation. For other clinically using drugs, either single injection or 5 day administration schedule was chosen according to administration schedule dependency of each drug. Life-prolonging activity was expressed by T/C obtained by comparing median or mean survival time of animals in drug-treated group (T) and that in control one (C).
Antitumor Experiments using HumanTumor Xenografts Four humanleukemic tumors and MX-1humanmammary tumor were implanted sc with a trocar into athymic nude mice. NKT-01was administered daily for 9 days after tumor volume reached about 300mm3. Tumor volume (V) was calculated as follows:
V=LxW2/2, where L and Ware length and width of tumor mass, respectively.
Results
Antitumor Effect of NKT-01 and SGL against Cultured Cells The growth inhibitory effect of SGL and NKT-01against 14 tumor cells is shown in Table 1 in terms ofIC50 values. The growth inhibition curves ofNKT-01 is presented in Figs. 1(A) and 1(B) . Great difference in sensitivity of tumor cells was observed to NKT-01as well as to SGL. The IC50 values of NKT-01for mouse P388, L1210
and L1210(IMC) leukemia cells were around 0.01 /ig/ml. In contrast, against rat AH66 and AH66F hepatomas, human MOLT-3 and NALM-6leukemias, NKT-01 inhibited only about 20%of the growth even at the highest concentration of 100//g/ml.
Although antitumor spectra of NKT-01and SGLagainst these cultured cells were similar each other, NKT-01was more potent than SGLin all tumors, the ratio of IC50 of SGLto NKT-01being about ten in average.
As shown in Figs. 1(A) and 1(B) , the growth inhibitory effect of NKT-01 was dependent very slightly on drug concentration and it tended to reach its plateau even at higher concentrations. The saturated level of the inhibitory effect in each tumor cells was parallel to IC50 value in general.
Antitumor Effect against Transplantable Murine Tumors The life-prolonging effect of NKT-01against 13 transplantable murine tumors are summarized in Table 2 . NKT-01 showed strong antitumor activity against all the 5 leukemias tested (P388, L1210, L1210 (IMC), C1498 and P815) irrespective of the site of implantation. Amongother non-leukemic tumors, NKT-01 exhibited potent activity against AH66F hepatoma, while its activity against M5076 fibrosarcoma, Lewis lung carcinoma and MH1 34 hepatoma was marginal, and it was ineffective against rest of the tumors.
The activities of NKT-01against L1210(IMC)leukemia and AH66Fhepatoma were extremely strong, and almost all animals survived at the optimal doses, which were rather lower as compared with its toxic dose. In other responsive tumors, T/C (%) values were around 200% and no long term survivors was obtained even at the optimal dose, which was just below the toxic dose.
As indicated by the chemotherapeutic index in Table 2 , the effective dose ranges of NKT-01 for sensitive leukemias and AH66Fhepatoma were very wide. The effectiveness of NKT-01was compared with various types of clinically useful antitumor agents in P388 and L1210 leukemias, which are widely used in evaluation of drug activity for their generally high sensitivity (Table 3) . NKT-01 produced the largest chemotherapeutic indexes, estimated from the dose range over 150%of T/C, although its maximal T/C's were not remarkable. NKT-01showed activity in 3-fold wider range than SGLdid in these leukemias, similarly to other tumor systems (data not shown).
Antitumor Effect against HumanTumor Xenografts The changes in relative tumor volumeof 5 humantumor xenografts implanted sc into nude mice following 9 day treatment with NKT-01 were shown in Fig. 2 . High dose of NKT-01 extremely inhibited the growth of J-l l l monocytic leukemia, of which tumor volume remained the same as the initial volume over 30 days, even though treatment had been completed in 9 days. Although high dose of NKT-01also showed inhibitory activity against other 3 leukemias and MX-1mammarytumor, no significant effect was observed at the lower dose.
Antitumor Activity of NKT-01 against P388 Leukemias Resistant to Other Antitumor Drugs To knowwhether NKT-01 shows cross-resistance to other antitumor drugs, chemotherapeutic activities of NKT-01against 5 resistant variants of P388 leukemia were compared with that against parental P388. As shown in Fig. 3 , no difference in efficacy was observed against the sensitive parental cell line and its Fig. 3 . Antitumor activity ofNKT-01againstparental Table 4 . Sensitivity of parental and NKT-01-resistant and five drug-resistant P388leukemiasin vivo. P388leukemiacells to various antitumor drugs in vitro. Numberin parentheses shows number of survivors 60 days after inoculation.
OCT. 1991 ADM-or Ara-C-resistant sublines. Although the T/C (%) values obtained in P388/CDDP, P388/5-FU and P388/ACNUwere lower than that obtained in sensitive P388 leukemia, NKT-01 retained the activity with maximal T/C (%) of 150% to 180%.
Sensitivity
of NKT-01-resistant P388 and SGL-resistant L1210(IMC) Leukemias to Other Antitumor Drugs To confirm the lack of cross-resistance of NKT-01 to other drugs, NKT-01-resistant P388 leukemia was established and sensitivity to various antitumor drugs was determined in vitro. As shown in Table 4 , the resistant cell line was 180-fold resistant to NKT-01and also resistant to SGL. No cross-resistance to other types of drugs was seen at all. In addition, P388/NKT-01showed slight collateral sensitivity to alkylating agents such as melphalan (L-PAM), ACNU,CDDPand mitomycin C (MMC).
Furthermore, in vivo sensitivities of P388/NKT-01 and L1210(IMC)/SGL leukemias to various antitumor drugs were examined. As shown in Table 5 , activities of drugs against resistant tumors were not inferior to those against sensitive tumors except that vincristine (VCR) showed cross-resistance to NKT-01 in L1210(IMC) leukemia (but not in P388/NKT-01). Moreover, although 5-FU and Ara-C showed the same activities in both pairs of tumors, other drugs including VCRexhibited higher activity against both or one of the two resistant tumors than each parental counterpart.
Discussion
In the present studies, NKT-01 exhibited antitumor activity against leukemias both in vitro and in vivo rather than against non-leukemic tumors. Especially, in the experiments using transplantable tumors, NKT-01showed strong activity against all the 5 leukemias tested. These results suggested that NKT-01 is active against leukemic tumors. This results was supported by the reported antileukemic activities of NKT-01 to the growth of 7V-butyl-7V-nitrosourea-induced rat leukemias. n) The effective dose range ofNKT-01in sensitive tumors was the widest amongrepresentative antitumor agents used in the clinic. It means that NKT-01has a good selective toxicity and that its activity does not strongly depend on injected dose intensity. This was correspondent with the slight dependency of the growth inhibitory activity on the concentration observed in vitro experiments. Weused humanserum in these in vitro experiments in place of usually used bovine serum, because NKT-01 is known to be oxidized by amine oxidase present in bovine serum at high concentration.12) Although thus oxidized molecules show cytocidal activity in a strongly concentration-dependent manner, Kuramochi et al. suggested this additional activity is not responsible for the activity observed in vivo. 13) Our results concerning the weak dependency on concentration observed in both in vitro and in vivo systems supported their conclusion. In addition, by using human serum in the in vitro studies, good correlation of sensitivity of tumors to NKT-01was obtained between in vitro cell culture and in vivo animal model; 3 mouse leukemias showed higher sensitivity than Lewis lung carcinoma, and J-l 1 1 showed higher sensitivity than U-937 both in vitro and in vivo experiments.
However, NKT-01showed remarkable activity against L1210(IMC) leukemia and AH66Fhepatoma in vivo especially at lower doses, although L1210(IMC) was less sensitive in vitro compared with LI210 and P388 leukemias, and AH66F was insensitive at all. This seemed to be due to host- NKT-01was shown to be lacking of cross-resistance to other antitumor agents by using 5 substrains of P388 leukemias resistant to ACNU,CDDP,ADM,5-FU and Ara-C. Essentially consistent results were reported by Harrison et al.16) Wefurther carried out the experiments using P388/NKT-01and L1210 (IMQ/SGLboth in vitro and in vivo and confirmed the lack of cross-resistance. From these results, it is likely that NKT-01 exhibits its efficacy by different mechanism(s) from other antitumor drugs examined in this study. Furthermore, collateral sensitivity to NKT-01was observed in these resistant cells especially in vivo. Therefore, NKT-01could be expected to be useful in the second or salvage therapy for some recurrent tumors as well as in primary therapy for leukemias.
